These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35653412)

  • 21. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
    Matsuoka K; Nakagawa F; Tanaka N; Okabe H; Matsuo K; Takechi T
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study.
    Bazarbashi S; Alkhatib R; Aseafan M; Tuleimat Y; Abdel-Aziz N; Mahrous M; Elsamany S; Elhassan T; Alghamdi M
    JCO Glob Oncol; 2024 Mar; 10():e2300461. PubMed ID: 38484194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
    Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Tsuji A; Tsuchihashi K; Sakai D; Ueno H; Tamura T; Yamashita K; Shimada Y
    Int J Clin Oncol; 2020 Apr; 25(4):614-621. PubMed ID: 31838590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
    Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
    Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study.
    Chida K; Kotani D; Nakamura Y; Kawazoe A; Kuboki Y; Shitara K; Kojima T; Taniguchi H; Watanabe J; Endo I; Yoshino T
    Ther Adv Med Oncol; 2021; 13():17588359211009143. PubMed ID: 33959196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States.
    Nevala-Plagemann C; Sama S; Ying J; Shen J; Haaland B; Florou V; Garrido-Laguna I
    J Natl Compr Canc Netw; 2023 Feb; 21(3):257-264. PubMed ID: 36812939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
    Patel AK; Abhyankar R; Brais LK; Duh MS; Barghout VE; Huynh L; Yenikomshian MA; Ng K; Fuchs CS
    Oncologist; 2021 Dec; 26(12):e2161-e2169. PubMed ID: 34406678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness.
    Giuliani J; Fiorica F; Ponturo G; Azzurro M; Ruzzenente A; Bonetti A
    J Oncol Pharm Pract; 2021 Jun; 27(4):974-977. PubMed ID: 33541208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study.
    Li RR; Zhou HJ; Zeng DY; Jiang SF; Liu W; Frühling P; Liu ZY
    J Gastrointest Oncol; 2024 Apr; 15(2):612-629. PubMed ID: 38756644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan.
    Kagawa Y; Shinozaki E; Okude R; Tone T; Kunitomi Y; Nakashima M
    ESMO Open; 2023 Aug; 8(4):101614. PubMed ID: 37562196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer.
    Walter T; Hawkins NS; Pollock RF; Colaone F; Shergill S; Ross PJ
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2575-2587. PubMed ID: 32715436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.
    Ogata M; Kotaka M; Ogata T; Hatachi Y; Yasui H; Kato T; Tsuji A; Satake H
    PLoS One; 2020; 15(6):e0234314. PubMed ID: 32530932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
    Coutzac C; Trouilloud I; Artru P; Henriques J; Masson T; Doat S; Bouché O; Coriat R; Saint A; Moulin V; Vernerey D; Gallois C; De La Fouchardière C; Tougeron D; Taieb J
    Clin Colorectal Cancer; 2022 Jun; 21(2):132-140. PubMed ID: 35337742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
    Chen J; Wang J; Lin H; Peng Y
    Med Sci Monit; 2019 Dec; 25():9179-9191. PubMed ID: 31790382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.
    Sunakawa Y; Kuboki Y; Watanabe J; Terazawa T; Kawakami H; Yokota M; Nakamura M; Kotaka M; Sugimoto N; Ojima H; Oki E; Kajiwara T; Yamamoto Y; Tsuji Y; Denda T; Tamura T; Ishihara S; Taniguchi H; Nakajima TE; Morita S; Shirao K; Takenaka N; Ozawa D; Yoshino T
    Target Oncol; 2024 Jan; 19(1):59-69. PubMed ID: 38194163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A Case of an Elderly Frail Patient with Unresectable Colorectal Cancer Controlled by Trifluridine/Tipiracil with Bevacizumab Therapy as a First-Line Treatment].
    Matsumoto R; Mori S; Toda H; Kita Y; Arigami T; Sasaki K; Kurahara H; Maemura K; Natsugoe S
    Gan To Kagaku Ryoho; 2021 Feb; 48(2):223-225. PubMed ID: 33597364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Regorafenib and Trifluridine and Tipiracil Hydrochloride Can Potentially Improve the Survival Time for Patients with Advanced or Recurrent Colorectal Cancer].
    Oki M; Nakamura A; Shinamura N; Sugaya T; Takagi K; Sugaya M
    Gan To Kagaku Ryoho; 2018 Sep; 45(9):1297-1303. PubMed ID: 30237371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study.
    Nose Y; Kagawa Y; Hata T; Mori R; Kawai K; Naito A; Sakamoto T; Murakami K; Katsura Y; Ohmura Y; Masuzawa T; Takeno A; Takeda Y; Kato T; Murata K
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):427-433. PubMed ID: 32816155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study.
    Sugita K; Kawakami K; Yokokawa T; Sugisaki T; Takiguchi T; Aoyama T; Suzuki K; Suenaga M; Yamaguchi K; Inoue A; Machida Y; Yamaguchi T; Hama T
    Oncology; 2016; 91(4):224-230. PubMed ID: 27513940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
    Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW
    Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.